Arbutus to present ab-729 and ab-161 data at the global hepatitis summit 2023

Two oral presentations scheduled for thursday, april 27, 2023 warminster, pa., april 18, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted as late-breaker oral presentations at the global hepatitis summit 2023 taking place april 25-28, 2023, in paris.
ABUS Ratings Summary
ABUS Quant Ranking